Furthermore, the combination of ganetespib and lapatinib treatments enhanced inhibition of tumor growth in both SKBR3 and SKBR3-L xenografts compared to monotherapy, suggesting a promising therapeutic strategy for HER2 + breast cancer. Here, ERBB2 is linked to breast cancer.